Aug. 5 at 8:45 PM
$JAZZ
🚨 🚨 🚨
Xywav revenue grew 13% YoY with 625 new patient adds
Total revenues increased 2% to
$1.05 billion in Q2
Strong cash position of
$1.7 billion with
$518.6 million operating cash flow in H1
Zepzelca granted Priority Review for 1L ES-SCLC with October PDUFA date
Share repurchases of
$125 million executed in Q2
Ziihera received European approval for HER2-positive biliary tract cancer
GAAP net loss of
$718.5 million vs. income of
$168.6 million in Q2 2024
Rylaze/Enrylaze sales declined 7% to
$100.7 million
Zepzelca sales decreased 8% to
$74.5 million due to increased competition
Non-GAAP adjusted net loss of
$504.8 million vs. income of
$360.7 million in Q2 2024
$905.4 million IPR&D expense from Chimerix acquisition impacting earnings
